191 related articles for article (PubMed ID: 22394569)
1. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity.
Suzuki F; Kubota T; Miyazaki Y; Ishikawa K; Ebisawa M; Hirohata S; Ogura T; Mizusawa H; Imai T; Miyasaka N; Nanki T
Arthritis Res Ther; 2012 Mar; 14(2):R48. PubMed ID: 22394569
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
3. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
[TBL] [Abstract][Full Text] [Related]
6. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
Chen F; Shu XM; Wang DX; Xie Y; Wang GC
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
[TBL] [Abstract][Full Text] [Related]
7. T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.
Houtman M; Ekholm L; Hesselberg E; Chemin K; Malmström V; Reed AM; Lundberg IE; Padyukov L
Arthritis Res Ther; 2018 Aug; 20(1):188. PubMed ID: 30157932
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis.
Jiang Q; Li Y; Xia L; Shen H; Lu J
J Interferon Cytokine Res; 2019 Nov; 39(11):720-725. PubMed ID: 31274382
[TBL] [Abstract][Full Text] [Related]
9. [Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits].
Chen F; Shu XM; Wang DX; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):204-8. PubMed ID: 22516988
[TBL] [Abstract][Full Text] [Related]
10. Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance.
Wu CY; Li L; Zhang LH
Eur J Med Res; 2019 Feb; 24(1):12. PubMed ID: 30764873
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory biomarkers in polymyositis/dermatomyositis patients with interstitial lung disease: a retrospective study.
Zhao J; Guo XJ; Shi L
Curr Med Res Opin; 2024 Jan; 40(1):113-122. PubMed ID: 37938089
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis.
Yuan L; Yao L; Zhao L; Xia L; Shen H; Lu J
Clin Exp Rheumatol; 2013; 31(3):428-32. PubMed ID: 23485578
[TBL] [Abstract][Full Text] [Related]
13. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.
Shimizu T; Tomita Y; Son K; Nishinarita S; Sawada S; Horie T
Clin Rheumatol; 2000; 19(5):352-9. PubMed ID: 11055823
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.
Liu T; Hou Y; Dai TJ; Yan CZ
Chin Med J (Engl); 2017 Sep; 130(17):2101-2106. PubMed ID: 28836555
[TBL] [Abstract][Full Text] [Related]
15. [The levels and clinical significance of serum B cell activating factor in Chinese patients with polymyositis or dermatomyositis].
Peng QL; Xie Y; Zhang RF; Shu XM; Wang GC
Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):210-3. PubMed ID: 22781895
[TBL] [Abstract][Full Text] [Related]
16. Serum KL-6 in adult patients with polymyositis and dermatomyositis.
Kubo M; Ihn H; Yamane K; Kikuchi K; Yazawa N; Soma Y; Tamaki K
Rheumatology (Oxford); 2000 Jun; 39(6):632-6. PubMed ID: 10888708
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
Ihn H; Asano Y; Kubo M; Yamane K; Jinnin M; Yazawa N; Fujimoto M; Tamaki K
Rheumatology (Oxford); 2002 Nov; 41(11):1268-72. PubMed ID: 12421999
[TBL] [Abstract][Full Text] [Related]
18. Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.
Zhou H; Wang Y; Bi K; Qi H; Song S; Zhou M; Chen L; Wang G; Duan T
Clin Rheumatol; 2019 May; 38(5):1425-1431. PubMed ID: 30645753
[TBL] [Abstract][Full Text] [Related]
19. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
[TBL] [Abstract][Full Text] [Related]
20. Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis.
Raouf J; Idborg H; Englund P; Alexanderson H; Dastmalchi M; Jakobsson PJ; Lundberg IE; Korotkova M
Arthritis Res Ther; 2018 May; 20(1):83. PubMed ID: 29720222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
